kabutan

Nxera Pharma Hits New Year-to-Date High on Second Development Milestone Achievement in Eli Lilly Partnership

Thu Apr 9, 2026 9:45 am JST Catalyst

Nxera Pharma <4565> surged, hitting a new year-to-date high. Before the market open, the company announced it had achieved the second development milestone under its research, development, and commercialization partnership with Eli Lilly targeting multiple targets in diabetes and metabolic diseases, drawing buying interest on the news. The milestone payment amount has not been disclosed. The impact on the consolidated earnings forecast for the fiscal year ending December 2026 has already been factored in.

Source: MINKABU PRESS

*Translated by generative AI. Click here for the original article.

Related Articles